A new partnership between the American Cancer Society and the Melanoma Research Alliance will fund research aimed at decreasing side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefits. FDA has approved use of checkpoint drugs to combat seven cancer types including lung, head and neck, kidney cancer, bladder cancer, Merkel...
At the end of her first day on the job as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, W. Kimryn Rathmell reflected on her decision to take the CEO job at the third largest cancer hospital in the United States.
